Printer Friendly

DECIDE: Decision-making within cells and differentiation entity therapies.

Project reference: 315902

Duration: From 2013-03-01 to 2017-02-28

Status : Active

Total cost: EUR 3 313 022

EU contribution: EUR 3 313 022

Objective: Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy. This type of therapy aims, using only mildly toxic treatments, to induce terminal maturation of leukaemia cells and accelerate their death. WP2 responds to the urgent need to devise milder treatments, especially for older and frailer AML patients. Participants have already identified a number of promising new therapeutic agents. Working across these two complementary areas will train our Early Stage Researchers (ESR) to understand the translation of new fundamental science into the development of new therapies. The ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy, so will provide an excellent scientific training in these areas. Secondments/visits by ESRs to participants who run centres of expertise in leading edge technologies will provide training in these; and the time spent with private sector participants, and the courses they provide, will ensure that ESRs acquire the transferable skills they will need if they are to work well in, and build bridges between, commercial and publicly funded research organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Poland s leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy.

Participants:

NATIONAL UNIVERSITY OF IRELAND, GALWAY

Ireland

University Road -

GALWAY, Ireland

Administrative contact: Mari Vahey

Tel.: +353 91 49 59 39

UNIVERSITAET BASEL

Switzerland

Petersplatz 1

BASEL, Switzerland

Administrative contact: Antonius Rolink

Tel.: +41 2671631

UNIWERSYTET WROCLAWSKI

Poland

Plac Uniwersytecki 1

WROCLAW, Poland

Administrative contact: Ewa Marcinkowska

Tel.: +48 71 375 2929

Fax: +48 71 375 2608

ORBSEN THERAPEUTICS LIMITED

Ireland

ORBSEN BUILDING NATIONAL UNIVERSITY OF IRELAND

GALWAY, Ireland

Administrative contact: Stephen Elliman

Tel.: +353 87 6545 486

INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL

United Kingdom

Old Brompton Road 123

LONDON, United Kingdom

Administrative contact: Yodry Vasquez

Tel.: +44 20 7 153 5296

INSTYTUT FARMACEUTYCZNY

Poland

UL. RYDYGIERA 8, LOK.

country :United Kingdom

2014 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2014 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:4EUIR
Date:Nov 8, 2014
Words:425
Previous Article:INTTOPSUP: Transport Properties of Emergent Edge States in Interacting Topological Superconductors.
Next Article:SPEECH IN CONTEXT: The neural implementation of contextual influences in speech perception.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters